ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2013
Adenovirus capsid-based anti-cocaine vaccine prevents cocaine from binding to the nonhuman primate CNS dopamine transporter.
Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 53 citations in OpenAlex.
- Incorporating meningeal immunity into vaccine development.Nature communications · 2025Review
- COT-TT vaccine attenuates induction and expression of cocaine-induced behavioral sensitization in rats: a dose-response study.Frontiers in psychiatry · 2025Article
- COT-TT vaccine attenuates cocaine-seeking and cocaine-conditioned place preference in rats.Human vaccines & immunotherapeutics · 2024Article
- Role of homologous recombination/recombineering on human adenovirus genome engineering: Not the only but the most competent solution.Engineering microbiology · 2024Review
- Vaccines to Treat Substance Use Disorders: Current Status and Future Directions.Pharmaceutics · 2024Review
- A humanized anti-cocaine mAb antagonizes the cardiovascular effects of cocaine in rats.Pharmacology research & perspectives · 2023Article
- Immunotherapeutic strategies for treating opioid use disorder and overdose.Expert opinion on investigational drugs · 2023Review
- Calix[Journal of advanced research · 2022Article
- A Review of Immunotherapeutic Approaches for Substance Use Disorders: Current Status and Future Prospects.ImmunoTargets and therapy · 2022Review
- Vaccine adjuvants to engage the cross-presentation pathway.Frontiers in immunology · 2022Review
- Adjuvants: Engineering Protective Immune Responses in Human and Veterinary Vaccines.Methods in molecular biology (Clifton, N.J.) · 2022Review
- A potent novel vaccine adjuvant based on straight polyacrylate.International journal of pharmaceutics: X · 2020Article
- Cocaine vaccine dAd5GNE protects against moderate daily and high-dose "binge" cocaine use.PloS one · 2020Article
- Neurophysiological Biomarkers of Parkinson's Disease.Journal of Parkinson's disease · 2020Article
- In vivo long-lasting alterations of central serotonin transporter activity and associated dopamine synthesis after acute repeated administration of methamphetamine.EJNMMI research · 2019Article
- Novel technologies in detection, treatment and prevention of substance use disorders.Journal of food and drug analysis · 2019Review
- Investigations into the efficacy of multi-component cocaine vaccines.Bioorganic & medicinal chemistry letters · 2018Article
- Efficient Syntheses of Cocaine Vaccines and TheirACS medicinal chemistry letters · 2018Article
- Augmenting the efficacy of anti-cocaine catalytic antibodies through chimeric hapten design and combinatorial vaccination.Bioorganic & medicinal chemistry letters · 2017Article
- Conjugate Vaccine Immunotherapy for Substance Use Disorder.Pharmacological reviews · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 1 country.
Funding
Abstract
Cocaine addiction is a major problem for which there is no approved pharmacotherapy. We have developed a vaccine to cocaine (dAd5GNE), based on the cocaine analog GNE linked to the capsid proteins of a serotype 5 adenovirus, designed to evoke anti-cocaine antibodies that sequester cocaine in the blood, preventing access to the CNS. To assess the efficacy of dAd5GNE in a large animal model, positron emission tomography (PET) and the radiotracer [(11)C]PE2I were used to measure cocaine occupancy of the dopamine transporter (DAT) in nonhuman primates. Repeat administration of dAd5GNE induced high anti-cocaine titers. Before vaccination, cocaine displaced PE2I from DAT in the caudate and putamen, resulting in 62±4% cocaine occupancy. In contrast, dAd5GNE-vaccinated animals showed reduced cocaine occupancy such that when anti-cocaine titers were >4 × 10(5), the cocaine occupancy was reduced to levels of <20%, significantly below the 47% threshold required to evoke the subjective 'high' reported in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.